

Effects of Pre-Procedure Activated Dimethacone on Mucosal Visibility during Oesophagogastroduodenoscopy: A Case-Control Study

AK Koushik¹, V Saketh², P Ganesh³, S Shanmughanathan⁴

ABSTRACT

Introduction: Dimethicone enhances diagnostic accuracy in Oesophagogastroduodenoscopy (EGD). Various regimens have been tried to ease the procedure for better mucosal visibility.

Aim: To evaluate the efficacy of activated dimethicone in improving endoscopic visibility.

Materials and Methods: The present prospective study was carried out from February 2017 to February 2018 in a tertiary teaching hospital, Chennai, India. A total of 2917 patients aged 18-70 years were enrolled for this study. The participants were divided into group S (1540 patients) and group C (1377 patients). Group S received activated dimethicone 30 minutes before the procedure and group C underwent procedure without any pre-procedure preparation. The mucosal visibility score was evaluated

in both the groups. Statistical analysis was conducted using IBM SPSS statistics (version 23.0). Unpaired student's t-test and Pearson Chi-Square test are used for statistical analysis of the data and in both, $p < 0.05$ was considered as significant level.

Results: The mucosal visibility score in oesophagus, stomach, antrum and duodenum was significantly better in group S patients compared to group C patients. Duration of endoscopy was significantly (p -value 0.0005) shorter (7.95 min) in the group S compared with the group C (8.17 min). The amount of flush used was on an average 3 mL less for group S than group C, which was also significant (p -value 0.0005).

Conclusion: Activated dimethicone pre-preparation to EGD significantly increased the mucosal visibility during procedure and decreased the endoscopy duration.

Keywords: Endoscopy, Simethicone, Upper gastrointestinal diseases

INTRODUCTION

The Oesophagogastroduodenoscopy (EGD) is the most common method suggested for upper gastrointestinal disease patients [1,2]. But, foam and bubbles can accumulate in the stomach and duodenum, reducing endoscopic visibility. Subtle lesions can be missed due to the foam and bubbles. This can decrease diagnostic accuracy and reduces patient comfort as it takes a lot of time clearing the foam and bubbles [3]. Activated dimethicone (polydimethylsiloxane and silicon dioxide or simethicone) has proven to be a good defoaming agent for use as an endoscopic premedication to remove bubbles. Activated dimethicone is not absorbed systemically following oral administration [4]. There are no significant side effects of Activated dimethicone reported till now. Activated dimethicone can be given up to 500 milligrams in a day without any systemic toxicity. Activated dimethicone reduces the surface tension of air bubbles, causing small bubbles to coalesce and collapse to release trapped air, thus reducing the foam and bubbles in the upper gastrointestinal tract [5,6].

This premedication regimen varies among different clinical practices. A recent meta-analysis study analysed 10 high quality studies comparing the efficacy of dimethicone with N-acetyl cysteine or alone intending to provide better basis for choosing the anti-foaming agent and conclusion faced heterogeneity in the methods used and inconsistency in the outcomes or statistical outputs [7]. There is not much literature regarding the efficacy of activated dimethicone in improving mucosal visibility during EGD in Indian population. Therefore, this study was planned to collect and analyse data from two EGD units, one unit using pre-procedure activated dimethicone and the other unit not using any preparation. From this data, we assessed the efficacy of activated dimethicone in improving endoscopic visibility in Indian population. The primary objective of

the present study was to assess the Total Mucosal Visibility Score (TMVS) and individual mucosal visibility scores. The secondary objectives included time taken for completion of EGD and amount of water flush used, assessing post-procedural bloating.

MATERIALS AND METHODS

This case-control study was conducted at a tertiary hospital in Chennai. This study was carried out between February 2017 and February 2018. The patient population included a fair representation from urban and rural areas. It includes people from varied socioeconomic strata. Institutional Ethics Committee approval (CSP-MED/17/JAN/33/26) was obtained for the study. This study included 2917 patients. The sample size was determined as per previous studies [8-10].


Inclusion criteria: All consecutive patients referred for routine EGD with a minimum age of 18 years were included in the study.

Exclusion criteria: Emergency cases, pregnant or breastfeeding women, patients with known stricture or stenosis of upper digestive tract and patients that already received activated dimethicone pre-endoscopy as part of their standard care within past 2 weeks were excluded from the study.

Written informed consent was collected from the study participants before performing EGD. Data was collected from two EGD units. Patients in both units were nil per oral for a period of 8 hours before the procedure. Group S received 125 mg of activated dimethicone (Nodis, Retort Pharmaceuticals, Chennai, India) in 60 mL of water 30 minutes prior to EGD. Patients of group C underwent EGD without any preparation. Patient allocation to each group was based on Out Patient Department Endoscopy Unit registration. Patients registered with unit I were allocated to group S and patients registered with unit II were allocated to Group C. Time taken for completion of study,

amount of water flushing, TMVS was recorded for each patient and compared between the two groups.

The mucosal visibility scoring was used as described by previous study [6]. Score 1: No adherent mucus; Score 2: Mild mucus not obscuring vision; Score 3: A large amount of mucus obscuring vision and requiring <50 mL water to clear; Score 4: Heavy adherent mucus requiring >50 mL water to clear [Table/Fig-1]. Scoring is done for each area noted in lower oesophagus, stomach (upper body, greater curve), antrum, and duodenum. Total Score ranges from 4 to 16. The Score of 4 indicates best mucosal visibility and 16 indicates poor mucosal visibility.



[Table/Fig-1]: Scoring of upper gastrointestinal endoscopy mucosal visibility. a) Score 1: No adherent mucus; b) Score 2: Mild mucus not obscuring vision; c) Score 3: A large amount of mucus obscuring vision and requiring <50 mL water to clear; d) Score 4: Heavy adherent mucus requiring >50 mL water to clear.

STATISTICAL ANALYSIS

The collected data were analysed with IBM. SPSS statistics software 23.0 Version. To describe about the data descriptive statistics, frequency analysis, percentage analysis were used for categorical variables and the mean and SD were used for continuous variables. To find the significant difference between the bivariate samples in independent groups, the unpaired sample t-test was used. To find the significance in categorical data chi-square test was used. In both the above statistical tools, the probability value ≤0.05 was considered as significant level.


RESULTS

This prospective study included 2917 (1579 men and 1338 women) patients, divided into group S and group C. Group S included 1540 patients and group C included 1377 patients. The demographic details of patients are tabulated in [Table/Fig-2]. The ages Mean±SD of group S and group C were 41±13 and 42±13, respectively. The age wise distribution of patients among the two groups was depicted in [Table/Fig-3]. The maximum number of patient was in age range of 21-60 years in both the groups. The ratios of male to female between group S and group C were 1:0.78 and 1:0.92, respectively. Majority of patients were diagnosed as oesophagitis (27.3%) and 25% were normal [Table/Fig-4]. The means of TMVS between group S and group C were 5.38 and 6.85, respectively. Group S had a significantly (p-value=0.0001) lower TMVS than group C.

The visibility scores of oesophagus, stomach, antrum and duodenum are shown in [Table/Fig-5]. The Mean Mucosal Visibility Scores (MMVS) of group S and group C at oesophagus region are 1.12 and 1.36, respectively. The MMVS of group S and group C at stomach region

Characteristics	Group S	Group C	p-value
Age (years) (Mean±SD)	41±13	42±13	0.04
Sex	Male	714	0.35
	Female	663	
Indications			N (%)
Dyspepsia (N)	749	664	1413 (48.4%)
Reflux (N)	488	426	914 (31.3%)
Anaemia (N)	203	156	359 (12.3%)
Minor UGI bleed (N)	25	30	55 (1.9%)
Variceal screening (N)	75	101	176 (6.0%)

[Table/Fig-2]: Patient demographic characteristics. N-frequency or number of patients. p-value less than 0.05 is considered significant.



[Table/Fig-3]: Age wise distribution of patients in study groups.

Diagnosis	Group S		Group C	
	N	%	N	%
Duodenal mucosal erosions	26	1.69%	25	1.82%
Duodenal mucosal erythema	34	2.21%	30	2.18%
Duodenal mucosal nodularity	8	0.52%	7	0.51%
Duodenal ulcer	66	4.29%	56	4.07%
Oesophagitis	420	27.27%	377	27.38%
Gastric growth	42	2.73%	27	1.96%
Gastric mucosal erosions	127	8.25%	108	7.84%
Gastric mucosal erythema	237	15.39%	212	15.40%
Gastric nodule	33	2.14%	32	2.32%
Gastric polyp	13	0.84%	9	0.65%
Gastric ulcer	47	3.05%	40	2.90%
Large oesophageal varices	6	0.39%	9	0.65%
Large oesophageal varices with GOV1	4	0.26%	6	0.44%
Large oesophageal varices with GOV2	7	0.45%	9	0.65%
Large oesophageal varices with severe PHG	15	0.97%	17	1.23%
MW tear	13	0.84%	10	0.73%
Normal mucosal study	397	25.78%	342	24.84%
Small oesophageal varices	15	0.97%	14	1.02%
Small oesophageal varices with GOV1	5	0.32%	10	0.73%
Small oesophageal varices with GOV2	3	0.19%	9	0.65%
Small oesophageal varices with Mild PHG	12	0.78%	13	0.94%
Small oesophageal varices with severe PHG	10	0.65%	15	1.09%

[Table/Fig-4]: Patient diagnoses. N-frequency or number of patients, %-Percentage. GOV 1: Gastroesophageal Varices extending along the lesser curvature of the stomach; GOV 2: Gastroesophageal Varices extending along the greater curvature towards the gastric fundus; PHG: Portal hypertensive gastropathy; MW: Mallory weiss

are 1.77 and 2.12, respectively. The MMVS of group S and group C at gastric antrum region are 1.39 and 1.9, respectively. The MMVS of group S and group C at duodenum region are 1.10 and 1.47, respectively.

Mucosal visibility Score		1	2	3	4	p-value
Oesophagus	Group S	1367	164	6	3	0.0005#
	Group C	995	292	73	17	
Stomach	Group S	595	745	156	44	0.0005#
	Group C	410	522	309	136	
Antrum	Group S	1069	365	78	28	0.0005#
	Group C	694	270	273	140	
Duodenum	Group S	1396	139	2	3	0.0005#
	Group C	921	291	141	24	
Group		MVSE Mean±SD	MVSS Mean±SD	MVSA Mean±SD	MVSD Mean±SD	TMVS Mean±SD
Group S		1.12±0.35	1.77±0.74	1.39±0.67	1.10±0.32	5.38±1.25
Group C		1.36±0.64	2.12±0.95	1.9±1.05	1.47±0.75	6.85±2.08
p-value		0.0001*	0.0001*	0.0001*	0.0001*	0.0001*

[Table/Fig-5]: Mucosal visibility Scores. p-value # calculated with Pearson Chi-Square test, *calculated with unpaired student's t-test. MVSE: Mucosal visibility score at oesophagus, MVSS: Mucosal visibility score at stomach; MVSA: Mucosal visibility score at antrum; MVSD: Mucosal visibility score at duodenum; TMVS: Total mucosal visibility score.

Group	Time taken for completion (min) Mean±SD	Amount of flush used (mL) Mean±SD	Post-procedure bloating	
			Present (N)	Absent (N)
Group S	7.95±0.88	8.57±23.04	615	925
Group C	8.17±0.98	12.24±26.84	768	609
p-value		0.0005*	0.0005*	

[Table/Fig-6]: Comparison of amount of flush, duration and post-procedure bloating of upper gastrointestinal endoscopy. p-value # calculated with Pearson Chi-Square test, *calculated with unpaired student's t-test.

The mean time taken for completion of procedure was 7.95 minutes and 8.17 minutes for group S and group C, respectively. The time taken was significantly low for group S patients. The mean amount of flush required was significantly low in group S (8.57 mL) than group C (12.24 mL). The post-procedure bloating was complained by 40% patients of group S and 56% patients of group C [Table/Fig-6].

DISCUSSION

This case-control prospective study is the first study of a preparatory solution containing simethicone for gastroscopy to be performed in Indian population. There was significant improvement in mucosal visibility of group S compared to group C. Hence, the findings of this study are similar to other studies that demonstrated improvements in gastric mucosal visibility with a pregastroscopy drink containing a defoaming agent. Secondary outcome measures demonstrated a marked reduction in the time taken for completion of the procedure; Post-procedural bloating and volume of flush required achieving adequate mucosal views in the group S receiving the active pregastroscopy drink. The present study showed that liquid simethicone solution was more effective in reducing obscuring foam and bubbles at all areas of upper gastrointestinal tract, enhancing endoscopic visibility.

According to literature, the effectiveness of simethicone in pre-procedure preparation for EGD was evaluated in few studies, and most studies evaluated the effectiveness of simethicone in preparation regimens of colonoscopy or capsule endoscopy [6,11,12]. A study by Keeratichananont S et al., included 121 patients for EGD and received simethicone (2 mL)+ 60 mL of water or placebo solution + 60 mL of water. They concluded that the mucosal visibility was clear in the simethicone group, but could not affect the duration of procedure [13]. This efficacy in increasing the mucosal visibility was also reported in a meta-analysis study [6].

Post-procedural bloating was statistically higher in group C patients compared to group S. Mean time taken for completion of the procedure was significant statistically in group C. The reduction in time taken for completion of procedure was seen in other study using simethicone by Ahsan M et al., [14]. Mean amount of flush

used was 8.57 mL in simethicone group where as it was 12.24 mL in control group with a p-value of 0.0005 which was highly significant statistically. This decrease in amount of flush was also reported by Chang CC et al., and Neale JR et al., but N-acetylcysteine was used in combination along with simethicone [15,16]. The mean TMVS was 5.38 in group S where as it was higher with a value of 6.85 in group C with a p-value of 0.0001 which was highly significant statistically.

The use of this preparatory solution is now standard practice in Japan and the Far East before gastroscopy [17]. They have yet to be widely utilised in the west and India. Cost of this pre-procedure drink is Rs. 6 per patient, which is representing very little extra cost in the context of benefits from this with marked improvement in mucosal visibility with less amount of flush required and faster completion time with less Post-procedural bloating.

Limitation(s)

This was not a double blinded randomised control trial which would have been ideal. The present study design might have bias in mucosal visibility scoring as it is highly subjective. Four observers were involved in this study though all were trained in endoscopy procedure.

CONCLUSION(S)

This study is first of its kind in India demonstrated that pre-procedure preparation with 125 mg simethicone + 60 mL of water, 30 minutes before the procedure was associated with improved overall endoscopic mucosal visibility. Its also associated with improved mucosal visibility at each of the 4 locations, reduced the need for endoscopic flushing, faster completion time and less Post-procedural bloating. In future, a double blinded randomised control trial can be planned in India to confirm the findings of this study and make this pre-procedure anti-foaming drink a standard for all EGDs in India to improve the mucosal visibility.

REFERENCES

- [1] Cohen J, Safdi MA, Deal SE, Baron TH, Chak A, Hoffman B, et al. Quality indicators for esophagogastroduodenoscopy. *Am J Gastroenterol.* 2006;101(4):886-91.
- [2] Ghanta MK, Gursale SC, Bhaskar LVKS. Understanding Colorectal Cancer: The Basics. In: Raju GSR, Bhaskar LVKS, editors. *Theranostics Approaches to Gastric and Colon Cancer.* Singapore: Springer Singapore. 2020;93-115.
- [3] Kwan V, Devière J. Endoscopy essentials: Preparation, sedation, and surveillance." *Endoscopy.* 2008;40(1):65-70.
- [4] Brecevic L, Bosan-Killbarda I, Strajnar F. Mechanism of antifoaming action of simethicone. *Journal of Applied Toxicology.* 1994;14(3):207-11.
- [5] Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomised placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. *Aliment Pharmacol Ther.* 2002;16(9):1641-48.
- [6] Wu L, Cao Y, Liao C, Huang J, Gao F. Systematic review and meta-analysis of randomised controlled trials of Simethicone for gastrointestinal endoscopic visibility. *Scand J Gastroenterol.* 2010;46(2):227-35.
- [7] Li Y, Du F, Fu D. The effect of using simethicone with or without N-acetylcysteine before gastroscopy: A meta-analysis and systemic review. *Saudi J Gastroenterol.*

- 2019;25(4):218-28.
- [8] Ray S, Patel H, Kotecha J, Parmar H. Analytical study of upper gastrointestinal endoscopy-200 cases. IAIM. 2016;3(9):98-102.
- [9] Takalkar UV, Kulkarni U, Kumar B, Takalkar M, Reddy DN. Diagnostic Yield of Upper Gastrointestinal Endoscopy with reference to Barrett's Esophagus in a Tertiary Care Center in India. SL Clin Med Oncol. 2017;1(1):01-12.
- [10] Hassan EA, Ahmed TI, Rajput S. Comparison of endoscopic findings in Egyptian and Indian patients: A retrospective cohort. Al-Azhar Assiut Medical Journal. 2019;17(1):54-60.
- [11] Ofstead, Cori L, Eiland JE, Wetzler HP. Widespread clinical use of simethicone, insoluble lubricants, and tissue glue during endoscopy: A call to action for infection preventionists. Am J Infect Control. 2019;47(6):666-70.
- [12] Jörg A, Göbel CM, Leßke J, Lotterer E, Nietsch H, Fleig WE. Simethicone for small bowel preparation for capsule endoscopy: A systematic, single-blinded, controlled study. Gastrointest Endosc. 2004;59(4):487-91.
- [13] Keeratichananont S, Sobhonslidsuk A, Kitiyakara T, Achalanan N, Soonthornpun S. The role of liquid simethicone in enhancing endoscopic visibility prior to esophagogastroduodenoscopy (EGD): A prospective, randomised, double-blinded, placebo-controlled trial. J Med Assoc Thai. 2010;93(8):892-97.
- [14] Ahsan M, Babaei L, Gholamrezaei A, Emami MH. Simethicone for the preparation before esophagogastroduodenoscopy. Diagn Ther Endosc. 2011;2011:484532.
- [15] Chang CC, Chen SH, Lin CP, Hsieh CR, Lou HY, Suk FM, et al. Premedication with pronase of N-acetylcysteine improves visibility during gastroendoscopy: An endoscopist-blinded, prospective, randomised study. World J Gastroenterol. 2007;13(3):444-47.
- [16] Neale JR, James S, Callaghan J, Patel P. Premedication with N-acetylcysteine and simethicone improves mucosal visualization during gastroscopy: a randomised, controlled, endoscopist-blinded study. Eur J Gastroenterol Hepatol. 2013;25(7):778-83.
- [17] Atar M, Kadayifci A. Transnasal endoscopy: Technical considerations, advantages and limitations. World J Gastrointest Endosc. 2014;6(2):41-48.

PARTICULARS OF CONTRIBUTORS:

1. Assistant Professor, Department of Medical Gastroenterology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
2. Consultant, Department of Medical Gastroenterology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
3. Professor, Department of Medical Gastroenterology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
4. Professor, Department of Medical Gastroenterology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. AK Koushik,
Assistant Professor, Department of Medical Gastroenterology, SRIHER-DU,
Chennai-116, Tamil Nadu, India.
E-mail: drakkoushik@gmail.com

PLAGIARISM CHECKING METHODS: [Jain H et al.]

- Plagiarism X-checker: Apr 25, 2020
- Manual Googling: May 18, 2020
- iThenticate Software: Jun 10, 2020 (11%)

ETYMOLOGY: Author Origin**AUTHOR DECLARATION:**

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. Yes

Date of Submission: **Apr 24, 2020**Date of Peer Review: **May 06, 2020**Date of Acceptance: **May 18, 2020**Date of Publishing: **Jul 01, 2020**